Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-649-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.99 million
Profitability
Miscellaneous
Employees173
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc (NASDAQ:XLRN) released its earnings results on Monday, August, 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.10. The biopharmaceutical company earned $27.67 million during the quarter, compared to the consensus estimate of $28.72 million. Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The firm's revenue for the quarter was up 649.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.63) earnings per share. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
12 Wall Street analysts have issued 1 year price objectives for Acceleron Pharma's shares. Their forecasts range from $45.00 to $78.00. On average, they anticipate Acceleron Pharma's stock price to reach $58.91 in the next twelve months. This suggests a possible upside of 36.6% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.
What is the consensus analysts' recommendation for Acceleron Pharma?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.
What are Wall Street analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
- 1. HC Wainwright analysts commented, "We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash." (9/17/2019)
- 2. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (7/20/2019)
Has Acceleron Pharma been receiving favorable news coverage?
News articles about XLRN stock have been trending negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acceleron Pharma earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Acceleron Pharma.
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), Moderna (MRNA), bluebird bio (BLUE), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), Ablynx (ABLYF), BioNTech (BNTX), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO).
What other stocks do shareholders of Acceleron Pharma own?
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
- Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
- Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
- Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include Neville Rodie & Shaw Inc. (0.06%), NJ State Employees Deferred Compensation Plan (0.02%), Nisa Investment Advisors LLC (0.01%) and Convergence Investment Partners LLC (0.01%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Christopher Rovaldi, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Institutional Ownership Trends for Acceleron Pharma.
Which major investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc.. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin and Ravindra Kumar. View Insider Buying and Selling for Acceleron Pharma.
Which major investors are buying Acceleron Pharma stock?
XLRN stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, NJ State Employees Deferred Compensation Plan and Convergence Investment Partners LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $43.12.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $2.27 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.
What is Acceleron Pharma's official website?
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
